Finding the trends behind the figures – what pharma's financial results reveal about where the industry is heading

10 April 2017

With the last set of 2016 financial results of a big-name pharma presented last week, it is possible – when they are viewed in a wider context – to gain some insight into the direction of the industry in analyzing the performance, outlook and pipeline of many of the major players.

Aided by Ed Corbett, engagement manager at specialist management consultancy firm Novasecta, The Pharma Letter looks at the challenges and opportunities relating to specific companies and the wider industry.

Mr Corbett certainly believes that patterns and trends can start to appear when analyzing annual financials, even in a sector that looks long into the future.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK